Ulrik Cordes
Chief Executive Officer CBio
Biochemist with 25 years’ experience in Danish-, Belgian- and US-based Biotech and Pharma. Since 2002 in top-executive positions in industry leading companies within oncology hereof the past 12 years in biotech startups. Founder and CEO of Copenhagen-based Cbio A/S, a company dedicated to enabling cancer cure by bringing novel cell-based immunotherapies to patients worldwide.
Seminars
Thursday 26th February 2026
Panel Discussion: Navigating Patient Selection & Eligibility in Europe to Ensure Timely Access to Cell Therapies
8:30 am
- Examine the complexities of trial design across oncology and autoimmune indications, including comorbidities, inpatient requirements, and overlapping recruitment efforts
- Discuss the readiness of Europe’s academic and healthcare ecosystems, from educating rheumatologists and haematologists to training medical staff in managing CAR-T related toxicities
- Highlight strategies to streamline patient identification and enrolment, including earlier eligibility assessments and addressing barriers such as hospital capacity and fragile patient timelines
Thursday 26th February 2026
Armouring Effector Cells Against Oxidative Stress to Enhance Function & Persistence of T-Cell Based Therapies
2:30 pm
- Present preclinical findings demonstrating how oxidative stress armouring can protect TILs and maintain their antitumour activity
- Discuss how enhancing TIL resilience to oxidative damage could improve durability and therapeutic outcomes in solid tumours
